NaNa Keum

Dr. NaNa Keum

Harvard T.H. Chan School of Public Health
+1

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2019 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
NKN. Keum
N. Keum
DLDong Hoon Lee
Dong Hoon Lee
DGDarren Greenwood
Darren Greenwood
JMJ.E. Manson
J.E. Manson
EGEdward Giovannucci
Edward Giovannucci
Previous meta-analyses of randomized controlled trials (RCTs) of vitamin D supplementation and total cancer incidence and mortality found inconsistent results, and most included trials administered generally low doses of vitamin D (≤ 1100 IU/day). We updated the meta-analysis by incorporating recent RCTs that have tested higher doses of vitamin D supplements. PubMed and Embase were searched from the inception to November, 2018. Summary relative risks (RRs) and 95% confidence intervals (CIs) were estimated using a random-effects model. For total cancer incidence, 10 trials were included (6,547 cases; 3-10 years of follow-up; 54-135 nmol/L of attained levels of circulating 25(OH)vitamin D [25(OH)D] in the intervention group). The summary RR was 0.98 (95% CI, 0.93 to 1.03; P=.42; I2=0%). The results remained null across subgroups tested, including even when attained 25(OH)D levels exceeded 100 nmol/L (RR, 0.95; 95% CI, 0.83 to 1.09; P=.48; I2=26%). For total cancer mortality, 5 trials were included (1,591 deaths; 3-10 years of follow-up; 54-135 nmol/L of attained levels of circulating 25(OH)D in the intervention group). The summary RR was 0.87 (95% CI, 0.79 to 0.96; P=.005; I2=0%), which was largely attributable to interventions with daily dosing (as opposed to infrequent bolus dosing). No statistically significant heterogeneity was observed by attained levels of circulating 25(OH)D (Pheterogeneity=.83), with RR being 0.88 (95% CI, 0.78 to 0.98; P=.02; I2=0%) for ≤ 100 nmol/L and 0.85 (95% CI, 0.70-1.03; P=.11; I2=0%) for > 100 nmol/L. In an updated meta-analysis of RCTs, vitamin D supplementation significantly reduced total cancer mortality but did not reduce total cancer incidence.

24 January 2015 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
NKNaNa Keum
NaNa Keum
DGDarren Greenwood
Darren Greenwood
DLDong Hoon Lee
Dong Hoon Lee
RKRockli Kim
Rockli Kim
DADagfinn Aune
Dagfinn Aune
EGEdward L. Giovannucci
Edward L. Giovannucci
Adiposity, measured by body mass index, is implicated in carcinogenesis. While adult weight gain has diverse advantages over body mass index in measuring adiposity, systematic reviews on adult weight gain in relation to adiposity-related cancers are lacking. PubMed and Embase were searched through September 2014 for prospective observational studies investigating the relationship between adult weight gain and the risk of 10 adiposity-related cancers. Dose-response meta-analyses were performed using a random-effects model to estimate summary relative risk (RR) and 95% confidence interval (CI) for each cancer type. All statistical tests were two-sided. A total of 50 studies were included. For each 5kg increase in adult weight gain, the summary relative risk was 1.11 (95% CI = 1.08 to 1.13) for postmenopausal breast cancer among no- or low-hormone replacement therapy (HRT) users, 1.39 (95% CI = 1.29 to 1.49) and 1.09 (95% CI = 1.02 to 1.16) for postmenopausal endometrial cancer among HRT nonusers and users, respectively, 1.13 (95% CI = 1.03 to 1.23) for postmenopausal ovarian cancer among no or low HRT users, 1.09 (95% CI = 1.04 to 1.13) for colon cancer in men. The relative risk of kidney cancer comparing highest and lowest level of adult weight gain was 1.42 (95% CI = 1.11 to 1.81). Adult weight gain was unrelated to cancers of the breast (premenopausal women, postmenopausal HRT users), prostate, colon (women), pancreas, and thyroid. An increase in risk associated with adult weight gain for breast cancer was statistically significantly greater among postmenopausal women (Pheterogeneity = .001) and HRT nonusers (Pheterogeneity = .001); that for endometrial cancer was alike among HRT nonusers (Pheterogeneity = .04). Avoiding adult weight gain itself may confer protection against certain types of cancers, particularly among HRT nonusers.

11 April 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
SKSeong Rae Kim
Seong Rae Kim
KKKyuwoong Kim
Kyuwoong Kim
SLSang-Ah Lee
Sang-Ah Lee
SKSung Ok Kwon
Sung Ok Kwon
JLJong-Koo Lee
Jong-Koo Lee
SPSang Min Park
Sang Min Park
Whether the risk of gastric cancer varies by the types of meat consumption still remains disputable. The purpose of this meta-analysis was to identify the exact associations that red, processed, and white meat have with gastric cancer. We searched relevant studies in Medline, EMBASE, and the Cochrane Library before November 2018, including cohort and case-control studies. We used random-effect models to estimate the adjusted relative risk (RR), and Egger’s tests to evaluate publication bias. Through stepwise screening, 43 studies were included in this analysis (11 cohort studies and 32 case-control studies with 16,572 cases). In a meta-analysis for the highest versus lowest categories of meat consumption, both red (RR: 1.41, 95% confidence interval (CI): 1.21–1.66) and processed (RR: 1.57, 95% CI: 1.37–1.81) meat consumption were positively associated with gastric cancer risk, while white meat consumption was negatively associated with gastric cancer risk (RR: 0.80, 95% CI: 0.69–0.92). In a dose–response meta-analysis, the RRs of gastric cancer were 1.26 (95% CI: 1.11–1.42) for every 100 g/day increment in red meat consumption, 1.72 (95% CI: 1.36–2.18) for every 50 g/day increment in processed meat consumption, and 0.86 (95% CI: 0.64–1.15) for every 100 g/day increment in white meat consumption. The increase of white meat consumption may reduce the risk of gastric cancer, while red or processed meat may increase the risk of gastric cancer. Further studies are required to identify these associations, especially between white meat and gastric cancer.

29 March 2014 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
NKNaNa Keum
NaNa Keum
DADagfinn Aune
Dagfinn Aune
DGDarren Greenwood
Darren Greenwood
WJWoong Ju
Woong Ju
EGEdward L. Giovannucci
Edward L. Giovannucci

10 June 2014 in British Journal of Cancer
Verified
Journal Article
Open access
NKN Keum
N Keum
EGE Giovannucci
E Giovannucci
Observational studies suggest that effects of vitamin D may be stronger for cancer mortality than for incidence. Yet, existing randomised controlled trials (RCTs) of vitamin D supplementation have limited power to examine the relationships as their primary end points are not cancer incidence or mortality. Meta-analyses of RCTs of vitamin D supplementation and total cancer incidence and mortality were conducted. Over 2-7 years of duration, vitamin D supplementations had little effect on total cancer incidence (400-1100 IU per day, summary relative risk (RR)=1.00, 95% confidence interval (CI)=0.94-1.06, I(2)=0%; four RCTs with combined 4333 cases), but significantly reduced total cancer mortality (400-833 IU per day, summary RR=0.88, 95% CI=0.78-0.98, I(2)=0%, three RCTs with combined 1190 deaths). Over 2-7 years of duration, the benefit of vitamin D supplementation may be limited to cancer mortality.

1 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
JKJong Yeob Kim
Jong Yeob Kim
KLKeum Hwa Lee
Keum Hwa Lee
JKJeonghyun Kang
Jeonghyun Kang
EBEdith Borcoman
Edith Borcoman
ESEsma Saada-Bouzid
Esma Saada-Bouzid
GGGabriele Gamerith
Gabriele Gamerith
Hyperprogressive disease (HPD) is a recently acknowledged pattern of rapid tumor progression after the initiation of immune checkpoint inhibitors. HPD has been observed across various types of tumors and has been associated with poor survival. We performed a meta-analysis to identify baseline (i.e., prior to programmed cell death 1 [PD-1, PDCD1] / programmed cell death 1 ligand 1 [PD-L1, CD274] inhibitor therapy) patient factors associated with risks of developing HPD during PD-1/PD-L1 inhibitor therapy. We searched eight databases until 6 June 2019. We calculated the summary odds ratio (OR) and its 95% confidence interval (CI) using the random-effects model and explored between-study heterogeneity and small-study effects. A total of nine articles was eligible (217 HPD cases, 1519 cancer patients) for meta-analysis. There was no standard definition of HPD, and the incidence of HPD ranged from 1 to 30%. We identified twenty-three baseline patient factors, of which five factors were statistically significantly associated with HPD. These were serum lactate dehydrogenase (LDH) above the upper normal limit (OR = 1.89, 95% CI = 1.02–3.49, p = 0.043), more than two metastatic sites (OR = 1.86, 1.34–2.57, p < 0.001), liver metastases (OR = 3.33, 2.07–5.34, p < 0.001), Royal Marsden Hospital prognostic score of 2 or above (OR = 3.33, 1.96–5.66, p < 0.001), and positive PD-L1 expression status that was inversely correlated with HPD (OR = 0.60, 0.36–0.99, p = 0.044). Between-study heterogeneity was low. Evidence of small-study effect was found in one association (PD-L1 expression). Subset analyses of patients with non-small cell lung cancer showed similar results. Future studies are warranted to identify underlying molecular mechanisms and to test their roles as predictive biomarkers of HPD.